Sun Pharma Announces $11.75 Billion All-Cash Acquisition of Organon

• The acquisition is structured as an all-cash deal, indicating Sun Pharma will pay the full $11.75 billion purchase price without stock considerations
• Organon is a U.S.-based drugmaker being acquired by India's Sun Pharmaceutical Industries
• The transaction represents one of the larger pharmaceutical M&A deals, with an $11.75 billion valuation for Organon

Sun Pharma Announces $11.75 Billion All-Cash Acquisition of Organon

Indian pharmaceutical giant Sun Pharmaceutical Industries has agreed to acquire U.S.-based Organon & Co. in an all-cash transaction valued at approximately $11.75 billion, according to a joint statement released Sunday, April 26.

Key Details:

• Acquirer: Sun Pharmaceutical Industries (India)
• Target: Organon & Co. (United States)
• Deal Value: $11.75 billion
• Structure: All-cash transaction
• Announcement Date: April 26 (Sunday)

Companies Involved:

Sun Pharma, India's largest pharmaceutical company, is making a significant strategic move to acquire Organon, a U.S. drugmaker that was spun off from Merck in 2021. Organon focuses on women's health products, biosimilars, and established pharmaceuticals.

Market Implications:

This transaction represents one of the largest cross-border pharmaceutical acquisitions by an Indian company, signaling Sun Pharma's aggressive expansion into the U.S. market. The deal would substantially increase Sun Pharma's global footprint and diversify its product portfolio, particularly in specialty therapeutic areas.

The all-cash nature of the transaction demonstrates Sun Pharma's strong financial position and confidence in the acquisition's strategic value. For Organon shareholders, the deal offers immediate liquidity at a premium valuation.

This consolidation move reflects broader trends in the pharmaceutical industry, where companies are seeking scale, geographic diversification, and complementary product portfolios to drive growth amid patent expirations and increasing R&D costs.

The transaction remains subject to customary regulatory approvals and closing conditions. Further details regarding the premium paid, financing arrangements, and expected closing timeline were not disclosed in the initial announcement.